

Bellatora, Inc. (formerly, Oncology Medical, Inc)

Quarterly Disclosure Statement

September 30, 2016

Bellatora, Inc. (formerly, Oncology Medical, Inc.)

Quarterly Disclosure Statement

September 30, 2016

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Bellatora, Inc. (formerly, Oncology Medical, Inc.)

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: 10205 Barrel Ridge St. Las Vegas, Nevada 89183

Address 2: _____

Address 3: _____

Phone: (702) 518-6656

Email: atom@bellatoraecigars.com; Atombellatora@gmail.com

Website(s): www.bellatoraecigars.com

IR Contact – not applicable

Address 1: _____

Address 2: _____

Address 3: _____

Phone: _____

Email: _____

Website(s): _____

3) Security Information

Trading Symbol: ECGR

Exact title and class of securities outstanding:

CUSIP: 716563 101

Par or Stated Value: .0001

Total shares authorized: 2,000,000,000 as of: June 30, 2016

Total shares outstanding: 9,099,900 as of: June 30, 2016

Additional class of securities (if necessary):

Trading Symbol: not applicable

Exact title and class of securities outstanding: Series A Preferred Stock

CUSIP: not applicable

Par or Stated Value: .0001

Total shares authorized: 0 as of: June 30, 2016

Total shares outstanding: 0 as of: June 30, 2016

Transfer Agent

Name: Action Stock Transfer

Address 1: 2469 E. Fort Union Blvd, Suite 214 Salt Lake City, UT 84121

Address 2: _____

Address 3: _____

Phone: (801)274-1088

Is the Transfer Agent registered under the Exchange Act?* Yes: X No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: The name change of 'Oncology Med, Inc.' (ONCO) to "Bellatora Inc." and the 1 – 1,500 reverse split was announced 9/27/2016 and took effect at the open of business 9/28/2016.

Established in 2014, the team at Bellatora came into existence to fulfill the need for a simple, healthier, non-intrusive alternative to the often neglected and wonderful pastime of cigar smoking. Cigar smokers ourselves, we here at Bellatora came together to find an alternative that is a close to the real thing as possible yet eliminates the slew of negative factors that go along with smoking a cigar. What we have done has succeeded beyond our greatest expectations. Thanks to our enthusiastic and dedicated team, we have been able to breathe life into this often neglected and infrequent pastime by enabling one to once again enjoy cigar smoking at any time or place. Gone are the days where one must search for a suitable place to light up a cigar and no longer does one need to burden themselves in regards to setting enough time aside to smoke it from start to finish. Never again does one need to concern themselves about how to care for their fragile cigars so as not to damage them or worry about them drying out before they can be enjoyed. With Bellatora's e-cigars all these issues have simply vanished into thin air. We here at Bellatora have painstakingly created a premier electronic product with a well-received full line of unique and diverse flavors that provides this very experience.

On January 5, 2015, the Company entered into a merger transaction with Onco Merger Sub, Inc., a then newly-established Colorado corporation, whereby the successor company (Onco Merger Sub, Inc.) changed its name to Oncology Med, Inc.

On January 5, 2015, the Company effected a share exchange with a newly-established corporation, named Oracle Nutraceuticals Company, whereby Oracle Nutraceuticals issued 100 shares of its common stock in exchange for all of the issued and outstanding shares of Oncology Med, Inc., a Colorado corporation. This transaction became effective pursuant to a reorganization under the applicable provisions of Section 368(a) et seq. of the IRS Code of 1986, as amended. As the result of the reorganization, the public trading company, formerly known as Oncology Med, Inc., a Delaware corporation, and, subsequently, a Colorado corporation, became a wholly-owned subsidiary of Oracle Nutraceuticals Company while Oracle Nutraceuticals Company is deemed the successor entity which is now the reporting and publicly trading entity. As a result of this January 2015 reorganization, the liabilities of Oncology Med, Inc., \$221,916 of the \$261,916 payables, are at the wholly-owned subsidiary level.

On January 28, 2015, Bellatora, Inc. was established in Colorado. As the result of the trans-action represented by that certain technology and stock purchase agreement, Bellatora acquired Oracle Nutraceuticals Company and, thereafter, Oracle Nutraceuticals Company changed its name to Bellatora, Inc.

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

None

B. Any jurisdictions where the offering was registered or qualified;

Not applicable

C. The number of shares offered;

Not applicable

D. The number of shares sold;

E. The price at which the shares were offered, and the amount actually paid to the issuer;

Not applicable

F. The trading status of the shares; and

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Not applicable

5) Financial Statements – Filed Separately

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;

B. Statement of income;

- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. (“Annual Report,” “Quarterly Report” or “Interim Report”).

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

The financial statements are filed separately and incorporated herein by this reference.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer’s Business, Products and Services

Describe the issuer’s business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer’s current business operations;

The Company’s integrated production management system, known as OctoVise, is intended to be a complete solution for remote gathering, analyzing and reporting of key hydrocarbon production information. It employs ICSCADA™, a supervisory control and data acquisition (“SCADA”) system for network-based application developed by Outlaw Automation, Inc. (“Outlaw”). Supervisory control and data acquisition/SCADA is a system that allows for control of remote equipment and is commonly employed in the oil and gas industry for measuring production data. (SCADA is a long-established system of collecting data for a number of industries which establishes “best practices” while ICSCADA is a proprietary product developed by Outlaw.) ICSCADA, in turn, weds supervisory control and data acquisition with the latest internet technology allowing for access to remote data via a dedicated web page. OctoVise further weds the Outlaw ICSCADA natural gas optimization with our own proprietary oil optimization human machine interface. OctoVise’s primary application is the measurement and remote monitoring and reporting of production data from the field including production rate and volume for gas, oil, other liquids, produced water, pressures (e.g., wellhead, flowing, casing, etc.) and temperature. Data is collected and transmitted via telemetry to a remote monitoring station where it is stored on secure redundant servers. OctoVise’s proprietary software allows for interaction between its human machine interface with an unlimited range of supervisory control and data acquisition equipment resulting in a seamless input/output to the customer. Data is collated into a webpage format that can be customized to customers’ needs. Customizable alarms are programmable to alert the monitoring engineer to key critical events (e.g., water cut levels, pressure drops, etc.). The monitoring engineer creates and provides daily, monthly, quarterly and annual customizable reports for the customer while also allowing the customer access to the information via a secure website. This provides a centralized location for all production data of an individual field or groups of fields of a single operator. It also provides overall jurisdiction based information to be utilized by regulatory bodies. The customer will also receive alerts via text, email and/or voice message regarding alarmed events allowing for quick response and intervention.

Secondary Applications

OctoVise can easily integrate data flow from other applications that can be combined according to customers’ needs:

Production optimization for gas and oil. OctoVise utilizes the onsite flow computer and input/output in order to monitor and evaluate key elements allowing for identification of issues which have resulted or could result in decreased production. The human machine interface allows for automatic intervention based on pre-set alarmed events or remote

intervention by the monitoring engineer. Optimized gas and oil production results in higher net daily rates and may contribute to increased revenues.

Pipeline leak and bottleneck detection. Utilizing the Leak Detection System developed by Outlaw Automation the monitoring engineer can continuously monitor volumes, densities, temperatures, pressures and product deviations which is then analyzed via predictive models to detect pipeline leaks, breaks or blockages. Early detection can avoid significant lost product, minimize ecological damage, quickly identify product theft in real time and isolate pipeline flow restrictions due to wax, scale or damage/pressure drops along pipelines or at various points of the transportation network to identify production bottlenecks or tampering. OctoVise offers a means of integrating existing pipeline supervisory control and data acquisition monitoring systems into an all-encompassing storage and reporting solution.

Custody transfer monitoring. Further application of ICSCADA Leak Detection equipment to accurately measure product at custody transfer points is essential in reporting the volume of sales. It also allows for identification of theft at key points related to the custody chain (pipeline to storage tank, pipeline to refinery, storage tank to vessel, etc.).

B. Date and State (or Jurisdiction) of Incorporation:

April 13, 2014 in Colorado

C. the issuer's primary and secondary SIC Codes;

1389 OIL AND GAS FIELD SERVICES, NOT ELSEWHERE CLASSIFIED
8711 ENGINEERING SERVICES

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

OctoVise – the Company's integrated production management system – a complete solution for remote gathering, analyzing and reporting of key hydrocarbon production information. Its supervisory control and data acquisition/ SCADA is a system that allows for control of remote equipment and is commonly employed in the oil and gas industry for measuring production data._

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

See Section 6 above.

The issuer leases office space at 10205 Barrel Ridge St. Las Vegas, Nevada 89183.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial

owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Atom Miller, President, CEO and CFO, currently holds 9,000,000 shares of common stock.

Dr. William Walker, former CEO, held 101,630,250 shares of common stock, until the February 22, 2016 Equity Exchange Agreement Incident to Reorganization. He now holds 33,877 shares of common stock.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- A. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

See above In Section A.

9) **Third Party Providers**

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: Randall Goulding

Firm: Securities Counselors, Inc.

Address 1: 1333 Sprucewood Deerfield Illinois

Address 2: _____

Phone: 847-828-3700

Email: Randy@securitiescounselors.net

Accountant or Auditor

Name: Stephen Durland

Durland & Company

PO Box 49671
Greensboro, NC 27403
Phone: 561-253-4518
Email: Stephen.durland@gmail.com

Investor Relations Consultant: Not Applicable

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Atom Miller certify that:

1. I have reviewed this quarterly disclosure statement of Bellatora, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 22, 2016

[Date]

A handwritten signature in blue ink, appearing to read 'Atom Miller', with a stylized flourish at the end.

[CEO's Signature]